We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 25, 2022

No Difference in Radiologic Outcomes With Extended-Interval Natalizumab Dosing Compared With Standard Dosing

Multiple Sclerosis and Related Disorders

 

Additional Info

Disclosure statements are available on the authors' profiles:

Multiple Sclerosis and Related Disorders
No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: real-world evidence from MS PATHS
Mult Scler Relat Disord 2022 Jan 02;2022(0)103480, LZ Ryerson, RT Naismith, LB Krupp, et al

Further Reading